1. eLibrary
  2. SWSLHD Staff Publications
  3. Liverpool Hospital
Please use this identifier to cite or link to this item: https://swslhd.intersearch.com.au/swslhdjspui/handle/1/10978
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLuckett, T.-
dc.contributor.authorPhillips, J.-
dc.contributor.authorLintzeris, N.-
dc.contributor.authorAllsop, D.-
dc.contributor.authorLee, J.-
dc.contributor.authorSolowij, N.-
dc.contributor.authorMartin, J.-
dc.contributor.authorLam, L.-
dc.contributor.authorAggarwal, R.-
dc.contributor.authorMcCaffrey, N.-
dc.contributor.authorCurrow, D.-
dc.contributor.authorChye, R.-
dc.contributor.authorLovell, M.-
dc.contributor.authorMcGregor, I.-
dc.contributor.authorAgar, M.-
dc.date.accessioned2023-09-14T22:19:11Z-
dc.date.available2023-09-14T22:19:11Z-
dc.date.issued2016-
dc.identifier.issn14440903 (ISSN)-
dc.identifier.urihttps://swslhd.intersearch.com.au/swslhdjspui/handle/1/10978-
dc.description.abstractBackground: Australian clinical trials are planned to evaluate medicinal cannabis in a range of clinical contexts. Aims: To explore the preferences, attitudes and beliefs of patients eligible and willing to consider participation in a clinical trial of medicinal cannabis for poor appetite and appetite-related symptoms from advanced cancer. Methods: A cross-sectional anonymous survey was administered from July to December 2015 online and in eight adult outpatient palliative care and/or cancer services. Respondents were eligible if they were �18 years, had advanced cancer and poor appetite/taste problems/weight loss and might consider participating in a medicinal cannabis trial. Survey items focused on medicinal rather than recreational cannabis use and did not specify botanical or pharmaceutical products. Items asked about previous medicinal cannabis use and preferences for delivery route and invited comments and concerns. Results: There were 204 survey respondents, of whom 26 (13%) reported prior medicinal cannabis use. Tablets/capsules were the preferred delivery mode (n = 144, 71%), followed by mouth spray (n = 84, 42%) and vaporiser (n = 83, 41%). Explanations for preferences (n = 134) most commonly cited convenience (n = 66; 49%). A total of 82% (n = 168) of respondents indicated that they had no trial-related concerns, but a small number volunteered concerns about adverse effects (n = 14) or wanted more information/advice (n = 8). Six respondents volunteered a belief that cannabis might cure cancer, while two wanted assurance of efficacy before participating in a trial. Conclusion: Justification of modes other than tablets/capsules and variable understanding about cannabis and trials will need addressing in trial-related information to optimise recruitment and ensure that consent is properly informed. ? 2016 Royal Australasian College of Physicians-
dc.publisherBlackwell Publishing-
dc.subjectanorexia attitude cancer cannabis clinical trial Adolescent Adult Aged Aged, 80 and over Appetite Australia Clinical Trials as Topic Cross-Sectional Studies Female Health Knowledge, Attitudes, Practice Humans Logistic Models Male Medical Marijuana Middle Aged Neoplasms Patient Participation Patient Preference Self Report Young Adult medical cannabis advanced cancer appetite disorder Article brain cancer breast cancer cancer center cancer pain cannabis smoking cannabis use clinical trial (topic) cross-sectional study digestive system cancer drug capsule female genital tract cancer health belief hematologic malignancy human insomnia loss of appetite lung cancer major clinical study mental disease nausea oral spray outpatient care patient attitude priority journal prostate cancer suppository tablet taste disorder vaporizer very elderly weight reduction attitude to health complication drug effects neoplasm statistical model-
dc.titleClinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation-
dc.typeJournal Article-
dc.description.affiliatesCentre for Cardiovascular and Chronic Care, Faculty of Health, University of Technology Sydney, Sydney, NSW, Australia Discipline of Addiction Medicine, Central Clinical School, Sydney Medical School, Sydney, NSW, Australia Drug and Alcohol Services, South East Sydney Local Health District, NSW Health, Sydney, NSW, Australia School of Psychology, The University of Sydney, Sydney, NSW, Australia Palliative Care, Concord Repatriation General Hospital, Sydney, NSW, Australia School of Psychology, University of Wollongong, Wollongong, NSW, Australia Department of Clinical Pharmacology, School of Medicine and Public Health, University of Newcastle, Newcastle, NSW, Australia Palliative Care, Liverpool Cancer Therapy Centre, Liverpool Hospital, Sydney, NSW, Australia Palliative and Supportive Services, Flinders University, Adelaide, SA, Australia Sacred Heart Supportive and Palliative Care, St Vincent's Hospital, Sydney, NSW, Australia Palliative Care, Greenwich Hospital, HammondCare, Sydney, NSW, Australia Northern Clinical School, Sydney Medical School, HammondCare, Sydney, NSW, Australia Department of Psychopharmacology, Faculty of Science, The University of Sydney, Sydney, NSW, Australia The Ingham Institute of Applied Medical Research, Sydney, NSW, Australia South Western Sydney Clinical School, University of New South Wales, Sydney, NSW, Australia-
dc.identifier.doi10.1111/imj.13224-
dc.type.studyortrialArticle-
dc.identifier.journaltitleInternal Medicine Journal-
Appears in Collections:Liverpool Hospital

Files in This Item:
There are no files associated with this item.
Show simple item record


Items in Prosentient are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing

Find this article